then, Biogen Idec Inc has lost 3.58% as of 01/07/2016's recent price of $304.49. If you would have followed this HC Wainwright's recommendation on BIIB, you would have lost 3.57% of your investment in 149 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

GainersToday is a Financial Web Site that provides to investors and traders, stock market recommendations, rankings and financial news. GainersToday keeps track of more than 20,000 recommendations given by more than 200 Research Companies.

At GainersToday smart investors can instantly find and compare thousands of
stocks recommendations. You can see past performance of Research Companies,
Accuracy, Percentage Gains.

You can add alerts by stock or by Research Company when a new stock
recommendation is released.